Literature DB >> 18394125

Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy.

T Neimert-Andersson1, S Thunberg, L Swedin, U Wiedermann, G Jacobsson-Ekman, S-E Dahlén, A Scheynius, H Grönlund, M van Hage, G Gafvelin.   

Abstract

BACKGROUND: Allergen-specific immunotherapy (ASIT) is the only treatment of allergic disease that gives long-lasting relief of symptoms. However, concerns for safety and efficiency have highlighted the need for improvement of the therapy. We have previously suggested carbohydrate-based particles (CBPs) as a novel adjuvant and allergen carrier for ASIT. Our aim of this study was to evaluate the therapeutic potential of CBPs in ASIT, employing a mouse model for cat allergy.
METHODS: BALB/c mice were subcutaneously immunized with the recombinant (r) cat allergen Fel d 1 followed by intranasal challenge with cat dander extract (CDE). The sensitized mice were therapeutically treated with rFel d 1 covalently coupled to CBPs (CBP-rFel d 1). Airway hyper-reactivity (AHR), infiltration of leucocytes in bronchoalveolar lavage (BAL) fluid, allergen-specific serum immunoglobulin levels and in vitro splenocyte responses were evaluated.
RESULTS: Mice treated with CBP-rFel d 1 showed reduced features of allergic inflammation. They responded with (i) significantly decreased AHR and infiltration of eosinophils in BAL fluid after CDE challenge, (ii) the serum level of rFel d 1-specific IgE was reduced and the level of IgG(2)a was more pronounced after CBP-rFel d 1 treatment, and (iii) there was also a tendency of decreased allergen-specific cellular response.
CONCLUSIONS: Carbohydrate-based particles are effective tools as adjuvant and allergen carriers for use in ASIT and constitutes a promising strategy to improve allergy treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18394125     DOI: 10.1111/j.1398-9995.2008.01644.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  10 in total

Review 1.  [Allergen-specific immunotherapy in pet allergy - an update].

Authors:  U Raap; M Wagenmann; O Pfaar
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

Review 2.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

3.  Proteolytically inactive per a 10 allergen of Periplaneta americana modulates Th2 response and enhances IL-10 in mouse model.

Authors:  Deepsikha Srivastava; Amit Kumar Mehta; Naveen Arora; Shailendra Nath Gaur; Bhanu Pratap Singh
Journal:  J Clin Immunol       Date:  2010-01-14       Impact factor: 8.317

4.  In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity.

Authors:  Ola B Nilsson; Justus Adedoyin; Claudio Rhyner; Theresa Neimert-Andersson; Jeanette Grundström; Kurt D Berndt; Reto Crameri; Hans Grönlund
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

Review 5.  New vaccines for Mammalian allergy using molecular approaches.

Authors:  Marianne van Hage; Gabrielle Pauli
Journal:  Front Immunol       Date:  2014-03-14       Impact factor: 7.561

6.  Designing a multimer allergen for diagnosis and immunotherapy of dog allergic patients.

Authors:  Ola B Nilsson; Theresa Neimert-Andersson; Mattias Bronge; Jeanette Grundström; Ranjana Sarma; Hannes Uchtenhagen; Alexey Kikhney; Tatyana Sandalova; Erik Holmgren; Dmitri Svergun; Adnane Achour; Marianne van Hage; Hans Grönlund
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

7.  Design, production and immunomodulatory potency of a novel allergen bioparticle.

Authors:  Véronique Gomord; Virginie Stordeur; Anne-Catherine Fitchette; Elizabeth D Fixman; Guy Tropper; Lorna Garnier; Réjean Desgagnes; Sébastien Viel; Julie Couillard; Guillaume Beauverger; Sylvain Trepout; Brian J Ward; Ronald van Ree; Loic Faye; Louis-P Vézina
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

8.  Mouse Model of Cat Allergic Rhinitis and Intranasal Liposome-Adjuvanted Refined Fel d 1 Vaccine.

Authors:  Natt Tasaniyananda; Urai Chaisri; Anchalee Tungtrongchitr; Wanpen Chaicumpa; Nitat Sookrung
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

Review 9.  An update on molecular cat allergens: Fel d 1 and what else? Chapter 1: Fel d 1, the major cat allergen.

Authors:  B Bonnet; K Messaoudi; F Jacomet; E Michaud; J L Fauquert; D Caillaud; B Evrard
Journal:  Allergy Asthma Clin Immunol       Date:  2018-04-10       Impact factor: 3.406

Review 10.  Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.

Authors:  Isabella Pali-Schöll; Douglas J DeBoer; Claudia Alessandri; Ahmed Adel Seida; Ralf S Mueller; Erika Jensen-Jarolim
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.